Oragenics Inc (NYSEAMERICAN:OGEN) reported that as previously reported in its Annual Report for the year closed December 31, 2017, which was submitted on February 16, 2018, the audited financial statements had an unqualified audit view from its independent registered public accounting company that comprised a going concern focus of matter paragraph.
This announcement is made as per the NYSE American LLC Company – Guide Section 610(b), which mandates public announcement of the reception of an audit view containing a going concern paragraph. The announcement doesn’t represent any amendment or change to the firm’s financial statements or to its Annual Report for the year closed December 31, 2017.
Oragenics focus remains on becoming a pioneer in unique antibiotics against infectious ailment and on advancing effective cures for oral mucositis. The company has advanced two exclusive global channel deals with Intrexon Corporation and its subsidiary firms. These collaborations enable Oragenics to boost the development of much required new antibiotics that have capabilities to combat resistant strains of bacteria and the growth of biotherapeutics for oral mucositis as well as other conditions and diseases of the oral cavity, esophagus and throat.
In unrelated news, Oragenics reported that the company will be presenting at 2018 MicroCap Conference on April 9 and 10, 2018 in New York City. The MicroCap Event is a renowned conference for investors who specialize in microcap and small stocks.
It is a prospect to speak to and meet with management at some of the leading small firms, learn from different expert panels, and interact with other microcap investors. As per the update, this MicroCap Conference is planned to take place in New York City in the next month. Registration process is already done. These days will be full of company presentations, roundtables, expert panel discussions, 1-on-1 meetings and plenty of time to interact with other investors over drinks and food.